• Mon. Dec 11th, 2023

Latest News on Health Care Market Negotiations


Nov 21, 2023

Analysts at Jefferies are warning that Bayer is facing significant challenges on multiple fronts, which are driving the need to explore strategic options. The halt of a late-stage clinical trial of experimental cardiovascular drug asundexian has pushed financial risk to the edge, while share-price falls have increased sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that the German pharmaceutical-and-agricultural group may need to sell assets and scrap dividends in order to buy time. However, this may not be enough to enable the large-scale investments needed in its pharma business, according to Jefferies. As a result, the firm has cut its recommendation on the stock from “buy” to “hold.” Despite this, shares have traded 0.3% higher following Monday’s heavy losses. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8.

Leave a Reply